A Few Clouds 41°
Tag:

TPM3-NTRK Gene Fusion

News
FDA Approved Medicine Has Makings Of 'Excellent Cancer Drug,' Holy Name Doc Says FDA Approved Medicine Has Makings Of 'Excellent Cancer Drug,' Holy Name Doc Says
FDA Approved Medicine Has Makings Of 'Excellent Cancer Drug,' Holy Name Doc Says A Holy Name Medical Center physician says a new cancer drug recently approved by the Food and Drug Administration is a significant step in the right direction. Vitrakvi (Larotrectinib) is for adults and children with solid tumors who test positive for TPM3-NTRK gene fusion, which Holy Name oncologist, Dr. Elan Diamond, likened to an on-switch that certain cancers depend on for growth and survival. Shutting off the switch can shut off the cancer. "It's a very fascinating development," he said. "This is one of the newest iterations of what we consider to be targeted treatment for cancer…

SHARE

by Cecilia Levine